FDMT 4D Molecular Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1650648 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY79,952.5%
TTM net income YoY4.2%
TTM EPS YoY28.0%
Revenue 3-yr CAGR63.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-226.0%
Net margin-208.6%
FCF margin—
EBITDA margin-220.9%
Returns
ROE-56.7%
ROA-47.0%
ROIC (approx.)-53.7%
Asset turnover0.23x
Leverage & solvency
Liabilities / assets21.2%
Debt / equity0.06x
Current ratio6.15x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $85.21M | $37,000 | $20.72M | $3.13M | $18.04M |
| R&D expense | $195.70M | $141.30M | $97.10M | $80.25M | $61.36M |
| SG&A expense | $49.06M | $46.58M | $36.49M | $32.91M | $28.01M |
| Operating income | -$159.55M | -$187.84M | -$112.87M | -$110.03M | -$71.33M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$140.11M | -$160.87M | -$100.84M | -$107.49M | -$71.32M |
| EBITDA | -$154.85M | -$183.19M | -$108.66M | -$107.63M | -$69.81M |
| EPS (basic) | -2.42 | -2.98 | -2.58 | -3.32 | -2.57 |
| EPS (diluted) | -2.42 | -2.98 | -2.58 | -3.32 | -2.57 |
| Weighted avg. shares (diluted) | 57.93M | 53.94M | 39.13M | 32.35M | 27.73M |
| Balance sheet | |||||
| Cash & equivalents | $60.24M | $149.34M | $249.11M | $52.35M | $153.00M |
| Short-term investments | $342.41M | $275.54M | $39.12M | $161.20M | $94.78M |
| Receivables | — | — | — | $0 | $47,000 |
| Current assets | $413.13M | $434.93M | $296.59M | $220.51M | $256.28M |
| PP&E, net | $14.87M | $19.53M | $20.13M | $22.26M | $14.39M |
| Total assets | $566.71M | $560.38M | $339.89M | $261.85M | $353.49M |
| Current liabilities | $43.98M | $29.15M | $18.95M | $15.73M | $16.34M |
| Long-term debt | $0 | — | — | — | — |
| Total debt | $0 | — | — | — | — |
| Total liabilities | $61.05M | $49.78M | $32.06M | $30.51M | $34.38M |
| Shareholders' equity | $505.66M | $510.61M | $307.83M | $231.34M | $319.11M |
| Net debt | -$60.24M | — | — | — | — |
| Shares outstanding | 57.61M | 45.79M | 43.08M | 32.63M | 32.22M |
| Cash flow statement | |||||
| Operating cash flow | -$109.08M | -$134.59M | -$75.79M | -$86.69M | -$69.13M |
| Capital expenditure | $536,000 | $3.79M | $2.77M | $11.54M | $9.11M |
| Free cash flow | -$109.62M | -$138.37M | -$78.56M | -$98.22M | -$78.24M |
| Investing cash flow | -$92.97M | -$302.44M | $115.72M | -$17.05M | -$172.68M |
| Financing cash flow | $112.96M | $337.25M | $156.83M | $3.08M | $118.09M |
| Depreciation & amortization | $4.69M | $4.65M | $4.20M | $2.40M | $1.52M |
| Stock-based compensation | $22.02M | $26.12M | $19.66M | $17.12M | $13.80M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.